Lisata Therapeutics Profit Margin

The latest profit margin for LSTA is -96.18% as of March 2026. That compares with -19.31% in the prior-year period — down 398.1% year over year. That is below the Healthcare sector average of 15.58%. Investors often review this figure alongside Lisata Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, LSTA's profit margin moved from -19.31% to -96.18% — a 398.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Lisata Therapeutics's valuation or profitability profile.

Against Healthcare companies, LSTA currently prints -96.18% for profit margin, while the sector average sits near 15.58%. That is roughly 61818.5% below the sector mean. Large gaps often invite a closer look at Lisata Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Lisata Therapeutics converts resources into returns. At -96.18%, LSTA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -19.31% in the prior-year period — down 398.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LSTA's profit margin (-96.18%), review year-over-year change from -19.31%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.